Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians Free

Abstract

Serology has been used to indicate past infection by the human polyomaviruses BK virus (BKV) and JC virus (JCV), because the site of primary infection is not established fully. Little is known about BKV and JCV antibody stability over time. We investigated BKV and JCV seroprevalence and antibody stability over time in an Australian population-based study. Serum was collected from 458 adults participating in a longitudinal skin cancer study in Queensland in 1992, 1993 and 1996, and 117 people had a fourth sample collected in 2003. Serum samples were analysed for BKV and JCV VP1 antibodies by multiplex detection using the Luminex platform. The seroprevalence for BKV and JCV over 4.5 years was 97 and 63 %, respectively. The BKV seroprevalence was 99 % in 25–60-year-olds, and 94 % in people older than 60 years. JCV seroprevalence was around 60 % in people younger than 50 years, 68 % in people 50–70 years of age and 64 % in people older than 70 years. BKV seroprevalence was very stable over 11 years, with 96 % of people staying seropositive and 2 % remaining seronegative. JCV antibody status over time was less stable; 57 % of participants remained seropositive and 31 % seronegative. The same proportion of people (4 % each) seroconverted, seroreverted or had fluctuating JCV antibody levels. These results confirm the previously believed stability of polyomavirus antibodies, with BKV antibodies being highly stable and JCV antibodies moderately so. Thus, a single measure can be used as a reasonable indicator of long-term antibody status in epidemiological studies aiming to understand associations between polyomaviruses and disease.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.020115-0
2010-07-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jgv/91/7/1849.html?itemId=/content/journal/jgv/10.1099/vir.0.020115-0&mimeType=html&fmt=ahah

References

  1. Abend, J. R., Jiang, M. & Imperiale, M. J.(2009). BK virus and human cancer: innocent until proven guilty. Semin Cancer Biol 19, 252–260.[CrossRef] [Google Scholar]
  2. Carter, J. J., Paulson, K. G., Wipf, G. C., Miranda, D., Madeleine, M. M., Johnson, L. G., Lemos, B. D., Lee, S., Warcola, A. H. & other authors(2009). Association of Merkel cell polyomavirus-specific antibodies with Merkel cell carcinoma. J Natl Cancer Inst 101, 1510–1522.[CrossRef] [Google Scholar]
  3. Gardner, S. D., Field, A. M., Coleman, D. V. & Hulme, B.(1971). New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet 1, 1253–1257. [Google Scholar]
  4. Gordon, J., Krynska, B., Otte, J., Houff, S. A. & Khalili, K.(1998). Oncogenic potential of human neurotropic papovavirus, JCV, in CNS. Dev Biol Stand 94, 93–101. [Google Scholar]
  5. Green, A., Williams, G., Neale, R., Hart, V., Leslie, D., Parsons, P., Marks, G. C., Gaffney, P., Battistutta, D. & other authors(1999). Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 354, 723–729.[CrossRef] [Google Scholar]
  6. Hamilton, R. S., Gravell, M. & Major, E. O.(2000). Comparison of antibody titers determined by hemagglutination inhibition and enzyme immunoassay for JC virus and BK virus. J Clin Microbiol 38, 105–109. [Google Scholar]
  7. Kean, J. M., Rao, S., Wang, M. & Garcea, R. L.(2009). Seroepidemiology of human polyomaviruses. PLoS Pathog 5, e1000363[CrossRef] [Google Scholar]
  8. Kjaerheim, K., Roe, O. D., Waterboer, T., Sehr, P., Rizk, R., Dai, H. Y., Sandeck, H., Larsson, E., Andersen, A. & other authors(2007). Absence of SV40 antibodies or DNA fragments in prediagnostic mesothelioma serum samples. Int J Cancer 120, 2459–2465.[CrossRef] [Google Scholar]
  9. Knowles, W. A., Pipkin, P., Andrews, N., Vyse, A., Minor, P., Brown, D. W. & Miller, E.(2003). Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 71, 115–123.[CrossRef] [Google Scholar]
  10. Maginnis, M. S. & Atwood, W. J.(2009). JC virus: an oncogenic virus in animals and humans? Semin Cancer Biol 19, 261–269.[CrossRef] [Google Scholar]
  11. Monaco, M. C., Jensen, P. N., Hou, J., Durham, L. C. & Major, E. O.(1998). Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection. J Virol 72, 9918–9923. [Google Scholar]
  12. Padgett, B. L., Walker, D. L., ZuRhein, G. M., Eckroade, R. J. & Dessel, B. H.(1971). Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1, 1257–1260. [Google Scholar]
  13. Randhawa, P., Bohl, D., Brennan, D., Ruppert, K., Ramaswami, B., Storch, G., March, J., Shapiro, R. & Viscidi, R.(2008). Longitudinal analysis of levels of immunoglobulins against BK virus capsid proteins in kidney transplant recipients. Clin Vaccine Immunol 15, 1564–1571.[CrossRef] [Google Scholar]
  14. Rollison, D. E., Helzlsouer, K. J., Lee, J. H., Fulp, W., Clipp, S., Hoffman-Bolton, J. A., Giuliano, A. R., Platz, E. A. & Viscidi, R. P.(2009). Prospective study of JC virus seroreactivity and the development of colorectal cancers and adenomas. Cancer Epidemiol Biomarkers Prev 18, 1515–1523.[CrossRef] [Google Scholar]
  15. Sehr, P., Zumbach, K. & Pawlita, M.(2001). A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. J Immunol Methods 253, 153–162.[CrossRef] [Google Scholar]
  16. Shivakumar, C. V. & Das, G. C.(1996). Interaction of human polyomavirus BK with the tumor-suppressor protein p53. Oncogene 13, 323–332. [Google Scholar]
  17. Stolt, A., Sasnauskas, K., Koskela, P., Lehtinen, M. & Dillner, J.(2003). Seroepidemiology of the human polyomaviruses. J Gen Virol 84, 1499–1504.[CrossRef] [Google Scholar]
  18. Waterboer, T., Sehr, P., Michael, K. M., Franceschi, S., Nieland, J. D., Joos, T. O., Templin, M. F. & Pawlita, M.(2005). Multiplex human papillomavirus serology based on in situ-purified glutathione S-transferase fusion proteins. Clin Chem 51, 1845–1853.[CrossRef] [Google Scholar]
  19. Weinreb, D. B., Desman, G. T., Amolat-Apiado, M. J., Burstein, D. E., Godbold, J. H., Jr & Johnson, E. M.(2006). Polyoma virus infection is a prominent risk factor for bladder carcinoma in immunocompetent individuals. Diagn Cytopathol 34, 201–203.[CrossRef] [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.020115-0
Loading
/content/journal/jgv/10.1099/vir.0.020115-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed